Slashdot Mirror

pogopop77 shares a report from Ars Technica: An appeals court will soon decide whether the U.S. government can unmask anonymous users of Glassdoor -- and the entire proceeding is set to happen in secret. Federal investigators sent a subpoena asking for the identities of more than 100 anonymous users of the business-review site Glassdoor, who apparently posted reviews of a company that's under investigation for potential fraud related to its contracting practices. The government later scaled back its demand to just eight users. Prosecutors believe these eight Glassdoor users are "third-party witnesses to certain business practices relevant to [the] investigation." The name of the company under investigation is redacted from all public briefs. Glassdoor made a compromise proposal to the government: it would notify the users in question about the government's subpoena and then provide identifying information about users who were willing to participate. The government rejected that idea. At that point, Glassdoor lawyered up and headed to court, seeking to have the subpoena thrown out. Lawyers for Glassdoor argued that its users have a First Amendment right to speak anonymously. While the company has "no desire to interfere" with the investigation, if its users were forcibly identified, the investigation "could have a chilling effect on both Glassdoor's reviewers' and readers' willingness to use glassdoor.com," states Glassdoor's motion (PDF). The government opposed the motion, though, and prevailed in district court.

Hugh Pickens DOT Com writes "Stephanie Smith reports at CNN that a coalition of more than 40 health care, consumer and addiction treatment groups is urging the Food and Drug Administration to revoke approval of the new prescription pain drug Zohydro, a hydrocodone-based drug set to become available to patients in March. 'You're talking about a drug that's somewhere in the neighborhood of five times more potent than what we're dealing with now,' says Dr. Stephen Anderson, a Washington emergency room physician who is not part of the most recent petition to the FDA about the drug. 'I'm five times more concerned, solely based on potency.' The concerns echoed by all groups are broadly about the drug's potency and abuse potential. They say they fear that Zohydro — especially at higher doses — will amplify already-rising overdose numbers. 'In the midst of a severe drug epidemic fueled by overprescribing of opioids, the very last thing the country needs is a new, dangerous, high-dose opioid (PDF),' the coalition wrote in a letter to FDA Commissioner Dr. Margaret Hamburg.

Zohydro's maker, Zogenix, and the FDA say the drug's benefits outweigh its risks and in their petition to the FDA for approval, Zogenix representatives say the drug fills a critical need for people suffering from chronic pain who are at risk for liver toxicity and cited examples of patients who might benefit from Zohydro: a 46-year-old male with chronic back and leg pain who had two failed back surgeries; a 52-year-old female with metastatic breast cancer experiencing diffuse pain; a 32-year-old woman with multiple orthopedic fractures. 'There's a lot of misinformation being put out there by people who don't have all the facts,' says Dr. Brad Galer, executive vice president and chief medical officer at Zogenix. 'We're talking about patients that are in bed, depressed, can't sleep, can't work, can't interact with their loved ones — it's a very significant medical health problem that is being ignored.'"

Hugh Pickens points out a story in the NYTimes about Texas' $4.93 billion wind-power transmission project. One of the major goals of the project is to improve electrical throughput to the population centers. Current transmission lines are unable to handle all of the power generated by Texas' wind fields. State citizens will be paying slightly more to help cover the cost, though the project is expected to eventually lower the cost to consumers. Quoting: "The lines can handle 18,500 megawatts of power, enough for 3.7 million homes on a hot day when air-conditioners are running. 'The project will ease a bottleneck that has become a major obstacle to development of the wind-rich Texas Panhandle and other areas suitable for wind generation. The lack of transmission has been a fundamental issue in Texas, and it's becoming more and more of an issue elsewhere,' said Vanessa Kellogg, the Southwest regional development director for Horizon Wind Energy, which operates the Lone Star Wind Farm in West Texas and has more wind generation under development. 'This is a great step in the right direction.'"

In our overly litigious society it seems that many companies are all too happy to fire off a cease-and-desist letter if they see something they don't like. Many times these letters end up online just causing further embarrassment for the company. One such company has decided to try scaring their targets out of this response by including a copyright notice for their cease-and-desist letter. Public Citizen has fielded one of these dumb letters and has invited them to try to assert their cease-and-desist copyright (which isn't even registered).

NewYorkCountryLawyer writes "In a landmark legal document, the Electronic Frontier Foundation, the American Civil Liberties Union, Public Citizen, the ACLU of Oklahoma Foundation, and the American Association of Law Libraries have submitted an amicus curiae brief in support of the motion for attorneys fees that has been made by Deborah Foster in Capitol Records v. Debbie Foster, in federal court in Oklahoma. This brief is mandatory reading for every person who is interested in the RIAA litigation campaign against consumers."